Vaxart reported a Q3 2024 revenue of $4.93 million, driven by BARDA contracts, with a continued cadence of high operating expenditures and a net loss of $14.08 million. The company posted an EBITDA loss of $11.21 million and an operating loss of $14.48 million, while maintaining a robust liquidity position with cash and investments totaling approximately $58.7 million and a net debt of about $1.04 million. Management emphasized the strength of their oral vaccine platform, including the COVID-19 Phase 2b trial enrolled in the sentinel cohort (400 participants) with completion of dosing anticipated soon, and constructive engagement with the FDA on Norovirus correlates of protection and program advancement. The company highlighted BARDA’s Project NextGen award, now valued up to $456 million, and reiterated its intent to pursue a rapid progression of the 10,000-subject second phase post-sentinel readout. The near-term path remains heavily weighted toward clinical execution and strategic partnering, with cash runway into 2026, but profitability remains contingent on successful clinical readouts and regulatory milestones.
Management stressed the potential long-term value of the oral vaccine platform, which aims to elicit mucosal immunity and improve delivery convenience relative to injectable vaccines. While the current quarter underscores substantial R&D and operating expenses relative to a nascent commercial revenue base, the company generated meaningful progress across its pipeline (COVID, Norovirus, and HPV) and continues to pursue a data-driven path toward Phase 2/2b readouts and potential licensure milestones. Investors should monitor the timing of the COVID sentinel cohort completion, any interim analyses, FDA feedback on Norovirus, and BARDA funding continuity as key catalysts that could impact the company’s liquidity and strategic optionality over the next 12–24 months.